Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712002 | 1.00 | KCNH2 (0.42) | KCNH2HTR1A | |
| SCHEMBL1723489 | 1.00 | KCNH2 (0.42) | KCNH2HTR1A | |
| SCHEMBL2289145 | 0.89 | KCNH2 (0.40) | KCNH2HTR1A | |
| SCHEMBL1722840 | 0.89 | KCNH2 (0.40) | KCNH2HTR1A | |
| SCHEMBL2294708 | 0.89 | KCNH2 (0.40) | KCNH2HTR1A | |
| SCHEMBL14385909 | 0.83 | KCNH2 (0.44) | KCNH2HTR1A | |
| SCHEMBL13319584 | 0.83 | KCNH2 (0.44) | KCNH2HTR1A | |
| SCHEMBL1722875 | 0.82 | KCNH2 (0.48) | KCNH2HTR1A | |
| SCHEMBL1712528 | 0.81 | KCNH2 (0.48) | KCNH2HTR1A | |
| SCHEMBL3550302 | 0.77 | KCNH2 (0.60) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822114-B2 | Tricyclic oxazolidinone antibiotic compounds | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-11-21 | — | — | US | disclosed |
| US-9487516-B2 | Antibacterial oxadiazolone derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2016-11-08 | — | — | US | disclosed |
| US-20160237088-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-08-18 | — | — | US | disclosed |
| US-9346804-B2 | Tricyclic oxazolidinone antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20150353547-A1 | Antibacterial Oxadiazolone Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-12-10 | — | — | US | disclosed |
| EP-2943492-A1 | ANTIBACTERIAL OXADIAZOLONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2015-11-18 | — | — | EP | disclosed |
| CN-104903322-A | Antibacterial oxadiazolone derivatives | ACTELION PHARMACEUTICALS LTD | 2015-09-09 | — | — | CN | disclosed |
| EP-2344495-B1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-12-31 | — | — | EP | disclosed |
| WO-2014108836-A1 | ANTIBACTERIAL OXADIAZOLONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-07-17 | — | — | WO | disclosed |
| US-20140142093-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-05-22 | — | — | US | disclosed |
| US-8618092-B2 | Tricyclic oxazolidinone antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-31 | — | — | US | disclosed |
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | HRH3, OXA1L, HRH1 | KCNH2 241/4885HTR1A 2667/4885 |
| US-20160237088-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | H1-3, HRH3, HRH4 | KCNH2 206/4885HTR1A 1898/4885 |
| US-20150353547-A1 | Antibacterial Oxadiazolone Derivatives | OXA1L, PYM1, XDH | KCNH2 192/4885HTR1A 3056/4885 |
| US-20140142093-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | OXA1L, H1-3, NGLY1 | KCNH2 261/4885HTR1A 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.